Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Ibrutinib (Primary) ; DTaP vaccine; Influenza virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Lymphoid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Oct 2015 Planned initiation date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 12 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top